Treatment of newly diagnosed diffuse brain stem gliomas in children: in search of the holy grail

References

• Fisher PG, Breiter SN, Carson BS et al. A clinicopathologic reappraisal of brain stem tumor classification. Identification of pilocytic astrocytoma and fibrillary astrocytoma as distinct entities. Cancer89, 1569–1576 (2000).
   PubMed Web of Science ®Google Scholar
• Freeman CR, Farmier JP. Pediatric brain stem gliomas: a review. Int. J. Radiation Oncol. Biol. Phys.40, 265–271 (1998).
   PubMed Web of Science ®Google Scholar
• Kaplan AM, Albright AL, Zimmerman RA et al. Brainstem gliomas in children. Pediatr. Neurosurg.24, 185–192 (1996).
   PubMed Web of Science ®Google Scholar
• Epstein F, McCleary EL. Intrinsic brain stem tumors of childhood: surgical indications. J. Neurosurg.64, 11–15 (1986).
   PubMed Web of Science ®Google Scholar
• Cartmill M, Punt J. Diffuse brain stem glioma – a review of stereotactic biopsies. Childs Nerv. Syst.15, 235–237 (1999).
   PubMedGoogle Scholar
• Albright AL, Price RA, Buthkelch AN. Brain stem gliomas of children. Cancer52, 2313–2319 (1983).
   PubMedGoogle Scholar
• Yoshimura J, Onda K, Tanaka R, Takahashi H. Autopsy series of 38 pontine gliomas. Neurol. Med. Chir.43, 375–382 (2003).
   PubMed Web of Science ®Google Scholar
• Mantravadi RV, Phatak R, Bellars S, Liebner EJ, Haas R. Brainstem glioma: an autopsy study of 25 cases. Cancer49, 1294–1296 (1982).
   PubMedGoogle Scholar
• Stroink AR, Hoffman HJ, Henrick EB, Humphries RP. Diagnosis and management of pediatric brain stem glioma. J. Neurosurg.65, 745–750 (1986).
   PubMedGoogle Scholar
• Albright AL, Guthkelch AN, Packer RJ, Price RA, Rourke LB. Prognostic factors in pediatric brain stem glioma. J. Neurosurg.65, 751–755 (1986).
   PubMed Web of Science ®Google Scholar
• Freeman CR, Suissa S. Brain stem tumors in children: results of a survery of 62 patients treated with radiotherapy. Int. J. Radiation Oncol. Biol. Phys.12, 1823–1828 (1986).
   Google Scholar
• Sure U, Ruedi D, Tachibana O et al. Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas. J. Neuropathol. Exp. Neurol.56, 782–789 (1997).
   PubMedGoogle Scholar
• Louis DN, Rubio MP, Correa KM, Gusella JF, Von Deimling A. Molecular genetics of pediatric brain stem glioma. Application of PCR techniques to small and archival brain tumor specimens. J. Neuropathol. Exp. Neurol.52, 507–515 (1993).
   PubMed Web of Science ®Google Scholar
• Cheng Y, Ng HK, Zhang SF et al. Genetic alterations in pediatric high grade astrocytomas. Human Pathol.30, 1284–1290 (1999).
   PubMed Web of Science ®Google Scholar
• Sung T, Miller DC, Hayes RL, Alonso M, Yee H, Newcomb EW. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Path.10, 249–259 (2000).
   PubMed Web of Science ®Google Scholar
• Gilberston RJ, Hill DA, Hernan R et al. ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin. Cancer Res.9, 3620–3624 (2003).
   PubMedGoogle Scholar
• Guillamo JS, Doz F, Delattre JY. Brain stem gliomas. Curr. Opin. Neurol.14, 711–715 (2001).
   PubMed Web of Science ®Google Scholar
• Sanford RA, Freeman CR, Burger P, Cohen ME. Prognostic criteria for experimental protocols in pediatric brain stem gliomas. Surg. Neurol.30, 276–280 (1988).
   PubMedGoogle Scholar
• Albright AL, Packer RJ, Zimmerman R, Rorke LB, Boyett J, Hammond GD. MR scans should replace biopsies for diagnosis of diffuse brain stem glioma: a report from the Children’s Cancer Group. Neurosurgery33, 1026–1030 (1993).
   PubMed Web of Science ®Google Scholar
• Packer RJ, Boyett JM, Zimmerman RA et al. Hyperfractionated radiation therapy (72 Gy) for children with brain stem gliomas. A Children’s Cancer Group Phase I/II trial. Cancer72, 1414–1421 (1993).
   PubMed Web of Science ®Google Scholar
• Packer RJ, Boyett JM, Zimmerman RA et al. Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy. A Childrens Cancer Group Phase I/II trial. Cancer74, 1827–1834 (1994).
   PubMedGoogle Scholar
• Chico-Ponce de Leon F, Perezpena-Diazconti M, Castro-Sierra E et al. Stereotactically-guided biopsies of brainstem tumors. Childs Nerv. Syst.19, 305–310 (2003).
   PubMedGoogle Scholar
• Zagzag D, Miller DC, Knopp E et al. Primitive neuroectodermal tumors of the brainstem: investigation of seven cases. Pediatrics106, 1045–1053 (2000).
   PubMedGoogle Scholar
• Knauer-Fischer S, Schaper J, Janssen HT, Ratjen F. Tuberculoma of the pons. Pediatric Neurology20, 57–59 (1999).
   PubMedGoogle Scholar
• Halpern EC, Constine LS, Tarbell NJ, Kun LE. Tumors of the posterior fossae and spinal canal. In: Pediatric Radiation Oncology 4th Edition. Lippincott Williams & Wilkins, PA, USA (2005).
   Google Scholar
• Langmoen IA, Lundar T, Storm-Mathisen I, Lie SO, Hovind KH. Management of pediatric pontine gliomas. Childs Nerv. Syst.7, 13–15 (1991).
   PubMed Web of Science ®Google Scholar
• Edwards MSB, Wara WM, Urtasum RC et al. Hyperfractionated radiation therapy for brain stem glioma: a Phase I–II trial. J. Neurosurg.70, 691–700 (1989).
   PubMed Web of Science ®Google Scholar
• Freeman CR, Krischer J, Sanford RA et al. Hyperfractionated radiation therapy in brain stem tumors. Results of treatment at the 7020 cGy dose level of POG study 8495. Cancer68, 474–81 (1991).
   PubMedGoogle Scholar
• Freeman CR, Krischer JP, Sanford RA et al. Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study. Int. J. Radiation Oncol. Biol. Phys.27, 197–206 (1993).
   PubMed Web of Science ®Google Scholar
• Prados MD, Wara WM, Edwards MSB, Larson DA, Lamborn K, Levin VA. The treatment of brain stem and thalamic gliomas with 78 Gy of hyperfractionated radiation. Int. J. Radiation Oncol. Biol. Phys.32, 85–91 (1995).
   PubMedGoogle Scholar
• Mandell LR, Kadota R, Freeman CR et al. There is no role for hyperfractionated radiation in the management of children with newly diagnosed diffuse intrinsic brain stem tumors: results of a Pediatric Oncology Group Phase III trial comparing conventional versus hyperfractionated radiation. Int. J. Radiation Oncol. Biol. Phys.43, 959–964 (1999).
   PubMed Web of Science ®Google Scholar
• Kanazawa H, Rappachietta D, Kallman RF. Schedule-dependent therapeutic gain from the combination of fractionated irradiation and cisdiemminedicholoroplatinum in C3H/Km mouse model systems. Cancer Res.48, 3158–3164 (1988).
   PubMed Web of Science ®Google Scholar
• Chastagner P, Kozin SV, Taghian A. Topotecan selectively enhances the radioresponse of human small cell lung cancer and glioblastoma multiforme xenografts in nude mice. Int. J. Radiation Oncol. Biol. Phys.50, 777–782 (2001).
   PubMedGoogle Scholar
• Freeman CR, Kepner J, Kun LE et al. A detrimental effect of a combined chemotherapy–radiotherapy approach in children with diffuse intrinsic brain stem gliomas. Int. J. Radiation Oncol. Biol. Phys.47, 561–564 (2000).
   PubMed Web of Science ®Google Scholar
• Packer RJ, Krailo M, Mehta M et al. Phase I study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brain stem glioma. Cancer104, 1281–1287 (2005).
   PubMedGoogle Scholar
• Allen J, Siffert J, Donahue B et al. A Phase I/II study of carboplatin combined with hyperfractionated radiotherapy for brainstem gliomas. Cancer86, 1064–1069 (1999).
   PubMed Web of Science ®Google Scholar
• Bernier-Chastagner V, Grill J, Doz F et al. Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas. Results of a French Society of Pediatric Oncology Phase II study. Cancer104, 2792–2797 (2005).
   PubMed Web of Science ®Google Scholar
• Sanghavi SN, Needle MN, Krailo MD, Geyer JR, Ater J, Mehta MP. A Phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of Children’s Cancer Group – 0952. Neuro-oncology5, 8–13 (2003).
   PubMed Web of Science ®Google Scholar
• Marcus KJ, Dutton SC, Barnes P et al. A Phase I trial of etanidozole and hyperfractionated radiation in children with diffuse brain stem glioma. Int. J. Radiation Oncol. Biol. Phys.55, 1182–1185 (2003).
   PubMedGoogle Scholar
• Blaney SM, Kun LE, Hunter J et al. Tumors of the central nervous system. In: Principles and Practice of Pediatric Oncology Fifth Edition. Pizzo PA, Poplack DG (Eds). Lippincott Williams & Wilkins, PA, USA 786–864 (2006).
   Google Scholar
• Jenkin RD, Boesel C, Ertel I et al. Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, vincristine, and prednisone. A report of the Children’s Cancer Study Group. J. Neurosurg.66, 227–233 (1987).
   PubMedGoogle Scholar
• Sposto R, Ertel IJ, Jenkin RD et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J. Neurooncol.7, 165–177 (1989).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Recurrent brainstem glioma treated with oral VP-16. J. Neurooncol.15, 133–139 (1993).
   PubMed Web of Science ®Google Scholar
• Korones DN, Fisher PG, Kretschmar C et al. Treatment of children with diffuse intrinsic pontine glioma with radiotherapy, vincristine, and oral VP-16: a Children’s Oncology Group Phase II Study. Pediatr. Blood Cancer DOI 10.1002/pbc.21154 (2007) (Epub ahead of print).
   Google Scholar
• Greenberg ML, Fisher PG, Freeman C et al. Etoposide, vincristine, and cyclosporine A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas: a Pediatric Oncology Group Phase I study. Pediatr. Blood Cancer45, 644–648 (2005).
   PubMed Web of Science ®Google Scholar
• Toth K, Vaughan MM, Peress NS, Slocum HK, Rustum YM. MDR1 P-glycoprotein is expressed by endothelial cells of newly-formed capillaries in human gliomas, but is not expressed in the neovasculature of other primary tumors. Am. J. Pathol.149, 853–858 (1996).
   PubMedGoogle Scholar
• Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352, 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Broniscer A, Iacono L, Chintagumpala M et al. Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children. Cancer103, 133–139 (2005).
   PubMed Web of Science ®Google Scholar
• Levin VA, Edwards MS, Wara WM, Allen J, Ortega J, Vestnys P. 5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the brain Tumor Research Center and the Childrens Cancer Group. Neurosurgery14, 679–681 (1984).
   PubMed Web of Science ®Google Scholar
• Wolff JEA, Westphal S, Molenkamp G et al. Treatment of paediatric pontine glioma with oral trophosphamide and etoposide. Br. J. Cancer87, 945–949 (2002).
   PubMedGoogle Scholar
• Walter AW, Gajjar A, Ochs JS et al. Carboplatin and etoposide with hyperfractionated radiotherapy in children with newly diagnosed diffuse pontine gliomas: a Phase I/II study. Med. Pediatr. Oncol.30, 28–33 (1998).
   PubMedGoogle Scholar
• Kretschmar CS, Tarbell NJ, Barnes PD et al. Pre-irradiation chemotherapy and hyperfractionated radiation therapy 66 Gy for children with brain stem tumors. A Phase II study of the Pediatric Oncology Group, Protocol 8833. Cancer72, 1404–1413 (1993).
   PubMedGoogle Scholar
• Jennings MT, Sposto R, Boyett JM et al. Preradiation chemotherapy in primary high-risk brainstem tumors: Phase II study CCG-9941 of the Children’s Cancer Group. J. Clin. Oncol.20, 3431–3437 (2002).
   PubMed Web of Science ®Google Scholar
• Doz F, Neuenschwander S, Bouffet E et al. Carboplatin before and during radiation therapy for the treatment of malignant brain stem tumours: a study by the Societe Francaise d’Oncologie Pediatrique. Eur. J. Cancer38, 815–819 (2002).
   PubMedGoogle Scholar
• Bouffet E, Raquin M, Doz et al. Radiotherapy followed by high dose busulfan and thiotepa. A prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas. Cancer88, 685–692 (2000).
   PubMed Web of Science ®Google Scholar
• Kedar A, Maria BL, Graham-Pole J et al. High-dose chemotherapy with marrow reinfusion and hyperfractionated irradiation for children with high-risk brain tumors. Med. Pediatr. Oncol.23, 428–436 (1993).
   Google Scholar
• Dunkel I, Garvin J, Goldman S et al. High-dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. J. Neurooncol.37, 67–73 (1998).
   PubMed Web of Science ®Google Scholar
• Jakacki RI, Siffert J, Jamison C, Velasquez L, Allen JC. Dose-intensive, time-compressed procarbazine, CCNU, vincristine (PCV) with peripheral blood stem cell support and concurrent radiation in patients with newly diagnosed high-grade gliomas. J. Neurooncol.44, 77–83 (1999).
   PubMed Web of Science ®Google Scholar
• Bouffet E, Khelfaoui F, Philip I, Biron P, Brunat-Mentigny M, Philip T. High-dose carmustine for high-grade gliomas in childhood. Cancer Chemother. Pharmacol.39, 376–379 (1997).
   PubMed Web of Science ®Google Scholar
• Allen J, Packer R, Bleyer A, Zeltzer P, Prados M, Nirenberg A. Recombinant β-interferon: a Phase I–II trial in children with recurrent brain tumors. J. Clin. Oncol.9, 783–788 (1991).
   PubMedGoogle Scholar
• Packer RJ, PRados M, Phillips P et al. Treatment of children with newly diagnosed brain stem gliomas with intravenous recombinant β-interferon and hyperfractionated radiation therapy: a Childrens Cancer Group Phase I/II study. Cancer77, 2150–2156 (1996).
   PubMed Web of Science ®Google Scholar
• Broniscer A, Leite CC, Lanchote VL et al. Radiation therapy and high-dose tamoxifen in the treatment of patients with diffuse brainstem gliomas: results of a Brazilian cooperative study. Brainstem Glioma Cooperative Group. J. Clin. Oncol.18, 1246–1253 (2000).
   PubMed Web of Science ®Google Scholar
• Turner CD, Chi S, Marcus KJ et al. Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. J. Neurooncol.82, 95–101 (2007).
   PubMed Web of Science ®Google Scholar
• Fine HA, Figg WD, Jaeckle K et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J. Clin. Oncol.18, 708–715 (2002).
   Google Scholar
• Bode U, Buchen S, Janssen G et al. Results of a Phase II trial of h-R3 monoclonal antibody (nimotuzumab) in the treatment of resistant or relapsed high-grade gliomas in children and adolescents. Proc. Am. Soc. Clin. Oncol.A1532 (2006).
   Google Scholar
• Daw NL, Furman WL, Stewart CF et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children’s Oncology Group study. J. Clin. Oncol.23, 6172–6180 (2005).
   PubMed Web of Science ®Google Scholar
• Magda D, Miller RA. Motexafin gadolinium: a novel redox active drug for cancer therapy. Semin. Cancer Biol.16, 466–476 (2006).
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res.13, 1253–1259 (2007).
   PubMed Web of Science ®Google Scholar
• Kunwar S, Prados MD, Chang SM et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J. Clin. Oncol.25, 837–844 (2007).
   PubMed Web of Science ®Google Scholar
• Wu Q, Guarnieri M, Tyler B et al. Local release of carboplatin via an Alzet mini-osmotic pump prolongs survival in a rat brainstem tumor model. Clin. Neurosurg.51, 332–339 (2004).
   PubMedGoogle Scholar
• Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med.352, 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med.353, 2012–2024 (2005).
   PubMed Web of Science ®Google Scholar
• Freeman CR, Krischer J, Sanford RA et al. Hyperfractionated radiotherapy in brain stem tumors: results of a Pediatric Oncology Group study. Int. J. Radiation Oncol. Biol. Phys.15, 311–318 (1988).
   PubMedGoogle Scholar